Amicus Therapeutics Is Maintained at Buy by UBS
UBS Maintains Amicus Therapeutics(FOLD.US) With Buy Rating, Raises Target Price to $22
Wells Fargo Maintains Amicus Therapeutics(FOLD.US) With Buy Rating, Cuts Target Price to $13
Express News | Goldman Sachs Maintains Neutral on Amicus Therapeutics, Lowers Price Target to $9
Amicus Therapeutics Analyst Ratings
Express News | Amicus Therapeutics Inc : UBS Raises Target Price to $22 From $21
Needham Maintains Amicus Therapeutics(FOLD.US) With Hold Rating
TD Cowen Maintains Amicus Therapeutics(FOLD.US) With Buy Rating, Maintains Target Price $20
Amicus Therapeutics' Earnings Call Highlights Growth and Strategic Moves
Amicus Therapeutics | 10-Q: Q1 2025 Earnings Report
Amicus Therapeutics Down Over 12%, on Pace for Largest Percent Decrease Since January 2022 -- Data Talk
Amicus Therapeutics Turns to Non-GAAP Q1 Earnings, Revenue Rises; Shares Down
Express News | Amicus Therapeutics Shares Are Trading Lower After the Company Reported Mixed Q1 Financial Results
Amicus Therapeutics (FOLD) Q1 Earnings and Revenues Lag Estimates
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Express News | Amicus Therapeutics Inc - Reiterates Gaap Profitability Expectation for H2 2025
Amicus Therapeutics Q1 Adj. EPS $0.03 Beats $(0.05) Estimate, Sales $125.20M Miss $135.86M Estimate
Earnings Flash (FOLD) Amicus Therapeutics Reports Q1 Adjusted EPS $0.03, Vs. FactSet Est of $0.08
Amicus Therapeutics Sees 2025 Rev Growth of 15% to 22% >FOLD
Express News | Amicus Therapeutics Q1 Operating Expenses USD 121.5 Million